Nyxoah SA: A Plain-English Investor Guide

This guide explains how Nyxoah SA is performing. My goal is to remove complex jargon so you can decide if this company fits your investment strategy.

1. What does this company do?

Nyxoah is a medical technology company treating Obstructive Sleep Apnea (OSA). Their flagship product, the Genio® system, is a neurostimulation device. Think of it as a "pacemaker" for the hypoglossal nerve that prevents airway collapse during sleep. Unlike traditional CPAP machines, Genio® is a battery-free, implantable solution. The company is currently scaling manufacturing to meet European demand and is finalizing the DREAM study to secure U.S. FDA approval, which is the gateway to the world’s largest OSA market.

2. Financial performance: The "Startup" Reality

Nyxoah is not yet profitable. For the year ending December 31, 2023, the company reported an operating loss of about €53.5 million, up from €44.9 million in 2022. Revenue remains modest at €4.3 million, mostly from sales in Germany and other European markets. The company is in a costly growth phase, with research and development (R&D) consuming €36.8 million in 2023 to fund clinical trials and regulatory work. They rely on selling more shares and taking on debt to bridge the gap until they reach profitability.

3. The "Going Concern" Warning

The latest filing includes a "going concern" note, meaning auditors are monitoring the company’s cash levels relative to its spending. As of December 31, 2023, Nyxoah held about €63.7 million in cash. Because the DREAM study and commercial expansion burn cash quickly, the company needs more funding within the next 12 months to keep operating. If they cannot raise money through new shares or debt, they may have to cut R&D or delay commercialization.

4. Major Wins and Challenges

• Wins: In 2023, Nyxoah secured a €25 million loan from the European Investment Bank, providing a needed cash buffer. They have also expanded the Genio® system to over 100 clinical centers across Europe and Australia.
• Challenges: Entering the U.S. market is the biggest hurdle. The DREAM study is a complex clinical trial; any delays or poor results would jeopardize FDA approval. Furthermore, the company faces tough competition from established players like Inspire Medical Systems. Even with approval, Nyxoah must convince insurers to pay for the device; low reimbursement rates could make the device unprofitable.

5. Key Risks for Investors

• Cash Flow: The company’s survival depends on raising more capital. Future share sales will likely reduce your ownership percentage.
• Regulatory Hurdles: Genio® is a high-risk medical device. If the FDA demands more data, U.S. sales could be delayed by years, increasing total costs.
• Cybersecurity: Genio® uses software for patient monitoring. Any software vulnerability could lead to recalls or loss of patient trust, which would be catastrophic for a company with only one product.
• Supply Chain: Nyxoah relies on a few specialized manufacturers. A disruption at these facilities could halt global sales, as the company cannot manufacture the device itself.

Bottom Line: Nyxoah is a high-risk, high-reward bet. You are investing in the potential of their technology to capture a large share of the OSA market. Success depends on the DREAM study, FDA approval, and raising enough cash to survive until they reach a self-sustaining scale. Before investing, consider whether you are comfortable with the volatility typical of a company that is still in its early, cash-burning growth phase.